Evaluation Through Innovative Examinations of Intestinal Dysbiosis Status in Patients Diagnosed With Cardiovascular Diseases and Evaluation of the Efficacy of Natural and Probiotic Extracts in the Non-pharmacological Approach to Improving Intestinal Dysbiosis Status.

ConditionAcute Coronary Syndromes (ACS)

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age30-70

SponsorCasa di Cura Dott. Pederzoli

About this trial

The prospective experimental study aims to take an instantaneous photograph of the subject at time T0 and after 24 hours of intestinal permeability and dysbiosis indices in patients with acute coronary syndromes (ACS) which include unstable coronary artery disease (unstable angina) and acute myocardial infarction (AMI). The aim is to verify whether essential oils in particular formulations with high bioavailability are able to re-establish intestinal eubiosis after 2 months, confirmed by tests laboratory specifics such as metabolomics.

Eligibility criteria

Qualifiers

1. Signing of informed consent

2. Diagnosis of Acute Coronary Syndrome (ACS)

3. Age 30-70

Disqualifiers

Diagnosis of conditions such as HIV, cancer and diabetes I and II Furthermore, if a female patient becomes pregnant during the trial, this will be one of the reasons for early exit from the study.

Trial design

Treatments tested in this trial

Tea tree (Melaleuca alternifolia), Cinnamon (Cynnamomum zeylanicum) bark, Clove carnation (Eugenia caryopyllus) flowers, Red thyme (Thymus vulgaris) plant

Treatment groups

15 Participants

are divided into 1 treatment group

Sponsors and collaborators

Casa di Cura Dott. Pederzoli

Lead sponsor

Herboplanet Srl

Collaborator

Source ClinicalTrials.gov